GB-115 is an oral protein-fragment medication, prescribed for anxiety in Russia, designed to block a brain messenger linked to fear and panic; elsewhere it circulates as an unregulated powder. Controlled trials, all run by its developer and manufacturer, show reduced anxiety and fatigue in adults with stress-related anxiety over four-week courses. Risks seen so far are mild. Safety beyond four weeks is unknown; any longevity role is untested. (Full Review)
| Marker | Target | Why |
|---|---|---|
| HARS total score | ≥50% fall from baseline by day 29 | Defines response |
| MFI-20 total score | ≤30 points | Tracks fatigue |
| Urine protein (dipstick) | Negative | Safety check; new proteinuria stops use |
| ALT and AST (liver enzymes) | Within laboratory upper limit, typically ≤40 U/L | Safety check; abnormal values place use outside tested conditions |
| eGFR (kidney filtration) | ≥60 mL/min/1.73 m² | Safety check; reduced values place use outside tested conditions |
| Pregnancy test (women of childbearing potential) | Negative | Safety check; positive result stops use |
Cadence: Baseline before starting; anxiety and fatigue scores at 2 weeks and at 4 weeks (day 29); urine protein and liver and kidney tests repeated at 4 weeks; the same panel before restarting and at the end of each further course